Monster Beverage
MNST
$44.20
+1.84%
Monster Beverage Corporation is a global leader in the energy drink category within the non-alcoholic ready-to-drink beverage market, with a portfolio spanning Monster Energy, Monster Ultra, Java Monster, Juice Monster, Reign, NOS, Burn, Bang, and Mother, plus a small alcohol brands business following a 2022 craft brewer acquisition; roughly two-thirds of revenue is generated in the US and Canada. The company operates an asset-light model, controlling branding and innovation while outsourcing manufacturing to co-packers and distribution to bottlers within the global Coca-Cola system under a 20-year agreement signed in 2015, with Coca-Cola holding a 20% stake — a structural moat that distinguishes it from smaller challengers. The current investor narrative centers on a sharp reacceleration in growth, with Q1 2026 revenue up 26.9% year over year to $2.35 billion and EPS of $0.58, alongside a 2-for-1 stock split completed on August 11, 2026 that has broadened retail participation. Debate now hinges on whether this growth burst is durable against intensifying competition from Celsius and other challengers, and whether the stock's premium multiple can be sustained after a recent pullback from its 52-week high.…
MNST
Monster Beverage
$44.20
Related headlines
Investment Opinion: Should I buy MNST Today?
We assign a Hold rating with a bullish bias. Monster's Q1 2026 revenue growth of 26.9% and industry-leading margins justify a premium valuation, but the stock's 33x forward PE and recent momentum weakness suggest limited near-term upside. The analyst consensus 'buy' rating and average target of $50.24 (15.8% upside) support a constructive view, but the wide target range ($35–$57) reflects uncertainty. We recommend accumulating on pullbacks toward the $38–$40 support zone.
The supporting evidence is compelling: revenue accelerated to $2.353 billion in Q1 2026 (+26.9% YoY), net margin expanded to 24.2%, and free cash flow reached $2.07 billion on a trailing basis. The balance sheet is debt-free with $2.04 billion in cash, and ROE of 23.1% demonstrates efficient capital use. The forward PE of 33.15x is below the stock's historical peak of 47x, but still double the sector average. The PEG ratio of 1.31 suggests the growth is reasonably priced, but not a bargain.
Key risks include potential multiple compression if growth decelerates, competitive threats from Celsius, and the stock's recent underperformance (-5.6% over one month). The rating would upgrade to Buy if the stock pulls back to the $38–$40 range (implying a forward PE near 29x) or if revenue growth sustains above 20% for another quarter. A downgrade to Sell would be warranted if gross margins fall below 54% or if revenue growth drops below 15%. Relative to its history and peers, Monster is fairly valued to slightly overvalued, but the quality of the business justifies a premium.
Sign up to view all
MNST 12-Month Price Forecast
Monster presents a balanced risk/reward at current levels. The company's fundamental strength is undeniable: 26.9% revenue growth, 24.2% net margin, and $2.07 billion in trailing free cash flow. However, the premium valuation (33x forward PE) and recent momentum deterioration suggest the market is pricing in continued execution. The analyst consensus is bullish, but the wide target range reflects uncertainty. We would upgrade to bullish if the stock pulls back to the $38–$40 range or if Q2 earnings show sustained 20%+ growth with margin expansion. Conversely, a downgrade to bearish would be warranted if revenue growth falls below 15% or gross margins slip below 54%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Monster Beverage's 12-month outlook, with a consensus price target around $50.24 and implied upside of +13.7% versus the current price.
Average Target
$50.24
0 analysts
Implied Upside
+13.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$35 - $57
Analyst target range
Coverage is robust with 23 analysts, and sentiment is firmly bullish: the consensus recommendation is "buy" with a recommendation mean of 2.04, and the average target price of $50.24 implies roughly 15.8% upside from the current $43.40. The consensus leans bullish, supported by a cluster of recent reiterations — Citigroup at Buy (July 14, 2026), Wells Fargo at Overweight (July 8, 2026), Morgan Stanley at Overweight (June 1, 2026), and Rothschild & Co upgrading to Buy from Neutral (May 6, 2026) — though JP Morgan and UBS both remain Neutral, indicating a meaningful minority that sees the stock as fully valued. The pattern of ratings is stable-to-improving, with no downgrades in the visible record, which suggests the sell-side is comfortable with the growth trajectory even after the recent price weakness. The target range is wide, from a low of $35.00 to a high of $57.00 — a spread of $22.00, or roughly 51% of the current price — which signals genuine disagreement about the durability of the growth reacceleration. The high target of $57.00 implies roughly 31% upside and likely assumes multiple expansion on sustained 20%+ revenue growth and continued margin gains, while the low target of $35.00 implies about 19% downside and prices in margin compression and share loss to Celsius and other challengers. The wide spread, combined with the fact that the low target sits below the current price, means the risk/reward is asymmetric but not overwhelmingly favorable; the consensus EPS estimate of $1.7675 (range $1.638–$1.854) and revenue estimate of $13.53 billion (range $12.77–$14.04 billion) show analysts are aligned on the near-term numbers but divided on the terminal value, which is typical for a premium-multiple consumer growth story facing intensifying competition.
Drowning in data?
Find the real signal!
Bulls vs Bears: MNST Investment Factors
The bull case rests on Monster's impressive Q1 2026 revenue reacceleration (+26.9% YoY), elite margins, debt-free balance sheet, and strong free cash flow, supported by a bullish analyst consensus. The bear case centers on the stock's premium valuation (33x forward PE), recent momentum deterioration, and intensifying competition. Currently, the bull evidence appears stronger given the fundamental outperformance and fortress financials, but the valuation leaves little margin for error. The single most important tension is whether the 26.9% revenue growth is sustainable; if it decelerates toward the sector average, the multiple could compress sharply, while sustained growth would justify the premium and drive the stock toward analyst targets.
Bullish
- Revenue growth reaccelerated sharply: Q1 2026 revenue grew 26.89% year over year to $2.353 billion, up from $1.855 billion in Q1 2025. This marks a significant acceleration from the ~14% growth in Q4 2025 and demonstrates that Monster's core energy drink franchise remains vibrant despite competitive noise.
- Elite profitability and fortress balance sheet: Q1 2026 net margin was 24.2%, gross margin 54.96%, and operating margin 31.02%, all best-in-class for the beverage sector. With zero debt-to-equity, a 3.70 current ratio, and $2.04 billion in cash, the company has virtually no financial risk.
- Strong free cash flow generation: Trailing free cash flow is $2.07 billion, with Q1 2026 FCF of $584.4 million on just $20.6 million of capex, a 29.4x capex coverage ratio. This asset-light model funds buybacks ($134 million in Q1) and cash accumulation without leverage.
- Analyst consensus bullish with upside: 23 analysts rate the stock a 'buy' with a mean recommendation of 2.04 and an average target price of $50.24, implying 15.8% upside from $43.40. Recent reiterations from Citigroup, Wells Fargo, and Morgan Stanley reinforce confidence.
Bearish
- Premium valuation vulnerable to compression: At 33.15x forward PE and 9.02x PS, Monster trades at roughly double the Consumer Defensive sector average. The PEG ratio of 1.31 leaves little room for error; any growth deceleration could trigger multiple contraction.
- Recent momentum deterioration: The stock is down 5.61% over the past month and 6.50% over three months, underperforming SPY by 4.55 and 9.54 percentage points respectively. This idiosyncratic weakness suggests stock-specific selling pressure despite a low beta.
- Intensifying competition from Celsius: Celsius's Q2 miss and declining flagship sales (per August 2026 news) highlight a fiercely competitive energy drink landscape. While Celsius's troubles may benefit Monster, the broader competitive intensity could pressure pricing and market share.
- Wide analyst target dispersion signals uncertainty: Target prices range from $35 to $57, a $22 spread (51% of current price). The low target implies 19% downside, reflecting genuine disagreement about the durability of the growth reacceleration and terminal value.
MNST Technical Analysis
Monster is in a sustained longer-term uptrend that has recently stalled: the stock is up 36.05% over the past year versus a 16.22% gain for SPY, a relative strength advantage of 19.83 percentage points, yet at $43.40 it sits only about 61.6% of the way through its 52-week range of $31.505 to $50.17. That positioning — well above the low but roughly 13.5% below the high — signals a stock that has given back a meaningful portion of its momentum rather than one pressing against resistance, and the 17.7% maximum drawdown confirms a real correction has occurred within the uptrend. For now the primary trend remains intact, but the failure to hold the upper quartile of the range argues for caution on chasing strength. Recent momentum has clearly decelerated and diverged from the longer-term trend: the stock is down 5.61% over the past month and 6.50% over three months, even as the 1-year and 6-month (12.57%) and YTD (13.97%) figures remain solidly positive. Relative strength versus SPY is negative across every short window — -4.55 points over 1 month and -9.54 points over 3 months — meaning Monster is underperforming a market that itself fell 1.06% in the past month, a classic sign of near-term distribution rather than mere beta-driven weakness. With a beta of just 0.515, the stock should be roughly half as volatile as the market, so this magnitude of underperformance is idiosyncratic and points to stock-specific selling pressure, likely tied to valuation concerns and competitive headlines around Celsius. Key levels are well defined: support rests at the 52-week low of $31.505, roughly 27% below the current $43.40, while resistance sits at the 52-week high of $50.17, about 15.6% above. A breakout above $50.17 would confirm the uptrend has resumed and likely open a new leg higher, whereas a breakdown below the $43 area — which has held repeatedly through September — would put the $38–$40 zone in play and threaten the intermediate trend; the low beta of 0.515 is a meaningful positive for risk management, allowing larger position sizes for the same portfolio volatility budget, but it also means the stock lacks the high-beta torque that drives sharp recoveries in risk-on rallies.
Beta
0.52
0.52x market volatility
Max Drawdown
-17.7%
Largest decline past year
52-Week Range
$32-$50
Price range past year
Annual Return
+36.7%
Cumulative gain past year
| Period | MNST Return | S&P 500 |
|---|---|---|
| 1m | -5.6% | -2.0% |
| 3m | -4.9% | +1.4% |
| 6m | +19.3% | +15.0% |
| 1y | +36.7% | +15.7% |
| ytd | +16.1% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MNST Fundamental Analysis
Monster's revenue trajectory has reaccelerated dramatically: Q1 2026 revenue reached $2.353 billion, up 26.89% year over year from $1.855 billion in Q1 2025, and up sequentially from $2.131 billion in Q4 2025 and $2.197 billion in Q3 2025. The segment mix shows Monster Energy Drinks at $2.189 billion, Strategic Brands at $126.7 million, and Alcohol Brands at just $32.7 million, meaning the core energy franchise is doing essentially all of the heavy lifting while alcohol remains immaterial. The multi-quarter arc — from $1.812 billion in Q4 2024 to $2.353 billion in Q1 2026 — represents roughly 30% growth over five quarters, an impressive acceleration for a company of this scale, though the sustainability of that pace against a resurgent Celsius is the central question for the investment case. Profitability is robust and improving: Q1 2026 net income was $569.5 million on a 24.2% net margin, with gross margin of 54.96% and operating margin of 31.02%, and EBITDA of $779.1 million (33.1% EBITDA margin). Gross margin has been remarkably stable in the 54.9%–55.7% band over the past five quarters, while net margin expanded from 21.1% in Q4 2025 to 24.2% in Q1 2026, and operating income rose to $730.0 million from $542.6 million sequentially. The company's 55.8% gross margin and 29.2% operating margin are elite for the non-alcoholic beverage industry, reflecting pricing power and the asset-light co-packer model, though the Q1 gross margin of 54.96% was slightly below the 55.53% reported in Q4 2025, suggesting modest input-cost or mix pressure worth monitoring. The balance sheet is fortress-like: debt-to-equity is 0, the current ratio is 3.70, and cash at the end of Q1 2026 was $2.04 billion, giving the company essentially no financial leverage risk. Free cash flow is powerful — $584.4 million in Q1 2026 alone and $2.07 billion on a trailing basis — with operating cash flow of $605.0 million against capital expenditures of just $20.6 million, a 29.4x capex coverage ratio that underscores how little capital the model consumes; ROE of 23.08% and ROA of 17.48% confirm high-quality capital efficiency, and the company returned capital via $134.0 million of stock repurchases in the quarter while still growing its cash pile.
Quarterly Revenue
$2.4B
2026-03
Revenue YoY Growth
+26.9%
YoY Comparison
Gross Margin
55.0%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MNST Overvalued?
Because Monster is solidly profitable — Q1 2026 net income of $569.5 million and trailing EPS of $0.0255 (post-split adjusted) — the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 39.32x versus a forward PE of 33.15x. The gap between trailing and forward multiples implies the market expects meaningful earnings growth, consistent with consensus EPS estimates of $1.7675 for the forward period; the PEG ratio of 1.31 suggests that growth is being paid for at a roughly fair, if not cheap, rate. On a price-to-sales basis the stock is expensive at 9.02x, and the EV/EBITDA of 27.94x and price-to-cash-flow of 35.66x both point to a premium valuation across every metric. Relative to the broader Consumer Defensive sector, which typically trades in the low-to-mid teens on forward earnings, Monster's 33.15x forward PE represents a substantial premium — roughly double the sector average — justified by its 26.9% revenue growth, 23.1% ROE, and 55.8% gross margin, all far above typical packaged-food and beverage peers. The premium is defensible only if growth remains in the mid-to-high teens or better; any deceleration toward the sector's low-single-digit growth would compress the multiple sharply, which is precisely the risk the recent 5.6% one-month decline appears to be pricing. Historically, Monster's PE has ranged from roughly 30x to 47x over the past several years, with the current 39.32x trailing and 33.15x forward sitting in the middle-to-lower portion of that band; the PS ratio of 9.02x is well below the 27x–35x levels seen in 2021–2023 (though those figures reflect pre-split share counts and different revenue bases), and the PB ratio of 9.07x is near the high end of its 7.0x–9.1x historical range. The takeaway is that Monster is not at a historical valuation extreme — it is cheaper than its 2021 peak multiples — but it is not cheap in absolute terms, and the market is clearly pricing in continued execution.
PE
39.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 30x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.9x
Enterprise Value Multiple
Investment Risk Disclosure
Monster's financial risks are minimal given its debt-free balance sheet (debt-to-equity of 0), $2.04 billion in cash, and 3.70 current ratio. However, the company's revenue is heavily concentrated in the core Monster Energy Drinks segment, which generated $2.189 billion of Q1 2026's $2.353 billion total revenue (93%). Any weakness in this flagship brand would have an outsized impact. Additionally, gross margin slipped sequentially from 55.53% in Q4 2025 to 54.96% in Q1 2026, and if input costs rise or promotional activity increases, profitability could face pressure. The asset-light model relies on third-party co-packers and Coca-Cola's distribution network, which introduces operational dependency risks.
Market and competitive risks are significant. The stock trades at a premium valuation (33.15x forward PE, 9.02x PS) relative to the Consumer Defensive sector, leaving it vulnerable to multiple compression if growth slows. Intensifying competition from Celsius and other challengers could erode Monster's market share and pricing power. The low beta of 0.515 means the stock is less sensitive to market swings, but it also lacks high-beta torque during rallies. Recent news highlights Celsius's Q2 miss and declining flagship sales, which could signal broader category headwinds or a shift in consumer preferences. Regulatory risks, such as potential labeling or marketing restrictions on energy drinks, also loom.
In a worst-case scenario, a combination of decelerating revenue growth, margin compression, and competitive share loss could drive the stock toward its 52-week low of $31.505, representing a 27.4% decline from the current $43.40. The analyst low target of $35.00 implies a 19.4% downside, and if the company misses earnings expectations or issues weak guidance, the stock could quickly re-rate to those levels. A breakdown below the $43 support level, which has held repeatedly, would likely accelerate selling pressure toward the $38–$40 zone. Given the premium valuation, a growth scare could trigger a 25-30% drawdown, erasing a significant portion of the 36% one-year gain.
FAQ
The key risks include: 1) Valuation risk: the premium multiple (33x forward PE) leaves little room for error; any growth deceleration could trigger a sharp re-rating. 2) Competitive risk: intensifying competition from Celsius and other challengers could erode market share and pricing power, as evidenced by Celsius's recent Q2 miss and declining flagship sales. 3) Margin risk: gross margin slipped sequentially from 55.53% to 54.96% in Q1 2026, and rising input costs or promotional activity could pressure profitability. 4) Concentration risk: 93% of revenue comes from the core Monster Energy Drinks segment, making the company vulnerable to a downturn in that category. 5) Macro/regulatory risk: potential regulations on energy drink marketing or labeling could impact sales. Ranked by severity, valuation and competitive risks are the most immediate, followed by margin and concentration risks.
Our 12-month forecast presents three scenarios: Bull case (25% probability) targets $57, assuming sustained 20%+ revenue growth and margin expansion. Base case (55% probability) targets $48–$52, assuming revenue growth moderates to 15-18% and margins remain stable. Bear case (20% probability) targets $35–$38, assuming growth decelerates to single digits and margins compress. The base case is most likely, supported by analyst estimates of $13.53 billion revenue and $1.77 EPS for 2026. The key assumption is that Monster maintains its premium valuation through consistent execution. If growth exceeds expectations, the stock could reach the bull target; if it disappoints, the bear case could materialize.
Monster trades at a premium valuation across multiple metrics: 33.15x forward PE, 9.02x PS, and 27.94x EV/EBITDA. Relative to the Consumer Defensive sector, which typically trades in the low-to-mid teens on forward earnings, Monster is roughly double the sector average. However, this premium is justified by its superior growth (26.9% revenue growth), profitability (24.2% net margin), and returns on equity (23.1%). Compared to its own history, the current forward PE of 33.15x is in the middle-to-lower portion of its 30x–47x range, suggesting it is not at an extreme. The PEG ratio of 1.31 indicates the growth is reasonably priced. Overall, the stock appears fairly valued to slightly overvalued, with the market pricing in continued execution. Any disappointment could lead to multiple compression.
Monster Beverage is a high-quality company with strong fundamentals, but the stock's premium valuation (33.15x forward PE) and recent momentum weakness (-5.6% over one month) suggest that now may not be the ideal entry point. The analyst consensus target of $50.24 implies 15.8% upside, which is attractive but not exceptional given the risks. The biggest downside risk is a growth deceleration that could compress the multiple, potentially sending the stock to the analyst low target of $35 (19% downside). For long-term investors, accumulating on pullbacks toward the $38–$40 support zone would offer a better risk/reward. For short-term traders, the stock's low beta (0.515) and recent underperformance make it less appealing. Overall, it is a good buy for patient investors seeking exposure to a dominant consumer growth story, but only at the right price.
Monster is best suited for long-term investment (minimum 2-3 years) given its strong brand, wide moat, and consistent free cash flow generation. The company does not pay a dividend, so returns depend on capital appreciation. Its low beta (0.515) makes it less volatile than the market, appealing to risk-averse investors. However, the premium valuation and competitive pressures introduce near-term uncertainty, making it less ideal for short-term trading. Earnings visibility is moderate; the next catalyst is the Q2 2026 earnings release. For long-term holders, the stock offers exposure to a dominant consumer growth story with a fortress balance sheet. We recommend a holding period of at least 2-3 years to ride out potential volatility and benefit from continued market share gains and international expansion.